MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Acute Myeloid Leukemia Research
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,888 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,888 works in the cohort · of 4,299,418page 33 of 58

Labels cover 3 of 2,888 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,888 of 2,888 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

venueno affunlabeled
Granulocytic sarcoma of the skin
Mario Pirisi, Marco Krengli, Guido Valente
2008· article· en· Canadian Medical Association Journal· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affunlabeled
Targeting MTHFD2 in Acute Myeloid Leukemia
Yana Pikman, Alexandre Puissant, Gabriela Alexe, Andrew Furman, Stacey M. Frumm, Linda S. Ross +12 more
2015· article· en· Blood· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affunlabeled
Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)
Rami S. Komrokji, María Diez‐Campelo, Lynette Chee, Thomas Cluzeau, Amy E. DeZern, Pierre Fenaux +18 more
2024· article· en· Blood· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) – Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial
Brian A. Jonas, Jörge E. Cortes, Samer K. Khaled, Giovanni Martinelli, Alexander E. Perl, Siddhartha Ganguly +17 more
2019· article· en· Clinical Lymphoma Myeloma & Leukemia· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affunlabeled
Pure erythroid leukemia
Méghan Forest, Simon F. Roy, Michelle Houde, Antonio Maietta
2020· article· en· Clinical Case Reports· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
← previousnext →

How this was built: Screen · Findings · About